MetaCap

Imunon (IMNN) vs Lantern Pharma (LTRN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantern Pharma is the larger company by market cap ($3.9 million vs $3.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNN-53.03%LTRN-73.08%
+14%-32%-77%
Oct 7, 20261 yearNov 20, 2026
IMNN-50.42%LTRN-69.85%
+19%-28%-74%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNN versus LTRN key metrics
MetricIMNNLTRN
Share price$0.5355$0.245
Market cap$3.47M$3.89M
1-day change-5.22%-13.73%
YTD return—-91.91%
1-year return—-91.89%
5-year return—-97.27%
EPS (TTM)$-3.31$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-14.50M$-17.12M
52-week high$4.35$4.34
52-week low$0.50$0.2286
Distance from 52-week high-87.69%-94.35%
Analyst consensusstrong_buynone
Avg. price target upside+3074.60%+7042.86%
Average volume150.49K249.66K
Shares outstanding6.49M15.89M
Employees2016
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Lantern Pharma

LTRN stock →

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

IMNN vs LTRN FAQ

Which is bigger, Imunon or Lantern Pharma?

Lantern Pharma (LTRN) is larger, with a market capitalization of $3.89M compared with $3.47M for Imunon (IMNN).

Are Imunon and Lantern Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons